Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Flexion Therapeutics Inc (FLXN) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Flexion Therapeutics Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1419600.
Total stock buying since 2014: $41,199,139.
Total stock sales since 2014: $7,146,351.
Total stock option exercises since 2014: $314,316.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2021 | 0 | $0 | 60,244 | $604,436 | 0 | $0 |
| 2020 | 12,307 | $119,993 | 24,064 | $26,253 | 18,450 | $40,497 |
| 2019 | 26,875 | $323,397 | 8,250 | $96,796 | 53,592 | $4,931 |
| 2018 | 23,000 | $468,674 | 50,000 | $1,253,484 | 57,068 | $6,145 |
| 2017 | 24,655 | $514,169 | 63,264 | $1,306,647 | 52,366 | $260,238 |
| 2016 | 2,227,691 | $31,249,906 | 10,000 | $184,630 | 10,369 | $1,690 |
| 2015 | 1,000 | $23,000 | 166,000 | $3,474,105 | 5,000 | $815 |
| 2014 | 500,000 | $8,500,000 | 10,000 | $200,000 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2021-07 | 0 | $0 | 13,704 | $88,389 | 0 | $0 |
| 2021-05 | 0 | $0 | 2,229 | $16,115 | 0 | $0 |
| 2021-03 | 0 | $0 | 4,520 | $53,336 | 0 | $0 |
| 2021-01 | 0 | $0 | 39,791 | $446,596 | 0 | $0 |
| 2020-07 | 0 | $0 | 0 | $0 | 18,450 | $40,497 |
| 2020-05 | 12,307 | $119,993 | 2,413 | $26,253 | 0 | $0 |
| 2020-01 | 0 | $0 | 21,651 | $0 | 0 | $0 |
| 2019-10 | 0 | $0 | 0 | $0 | 22,768 | $0 |
| 2019-08 | 4,317 | $46,617 | 0 | $0 | 30,824 | $4,931 |
| 2019-05 | 18,512 | $226,772 | 2,248 | $22,614 | 0 | $0 |
| 2019-03 | 4,046 | $50,008 | 0 | $0 | 0 | $0 |
| 2019-01 | 0 | $0 | 6,002 | $74,182 | 0 | $0 |
| 2018-11 | 9,000 | $151,695 | 0 | $0 | 0 | $0 |
| 2018-10 | 0 | $0 | 0 | $0 | 19,366 | $0 |
| 2018-08 | 14,000 | $316,979 | 0 | $0 | 0 | $0 |
| 2018-07 | 0 | $0 | 50,000 | $1,253,484 | 0 | $0 |
| 2018-05 | 0 | $0 | 0 | $0 | 37,702 | $6,145 |
| 2017-11 | 7,700 | $184,206 | 0 | $0 | 0 | $0 |
| 2017-10 | 0 | $0 | 0 | $0 | 19,366 | $0 |
| 2017-09 | 4,000 | $96,950 | 0 | $0 | 0 | $0 |
| 2017-08 | 1,375 | $34,925 | 0 | $0 | 0 | $0 |
| 2017-06 | 11,580 | $198,088 | 0 | $0 | 0 | $0 |
| 2017-05 | 0 | $0 | 6,830 | $130,453 | 0 | $0 |
| 2017-04 | 0 | $0 | 5,000 | $142,650 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-07-19 | Muzikant Adam (Chief Business Officer) | Sale | 1,870 | 6.45 | 12,061 |
| 2021-07-19 | Willwerth Christina (Chief Strategy Officer) | Sale | 3,945 | 6.45 | 25,445 |
| 2021-07-19 | Levine Mark S. (General Counsel) | Sale | 3,945 | 6.45 | 25,445 |
| 2021-07-19 | Wentworth Kerry (Chief Regulatory Officer) | Sale | 3,944 | 6.45 | 25,438 |
| 2021-05-10 | Arkowitz David (Chief Financial Officer) | Sale | 2,229 | 7.23 | 16,115 |
| 2021-03-15 | Layman Melissa (Chief Commercial Officer) | Sale | 4,520 | 11.80 | 53,336 |
| 2021-01-28 | Layman Melissa (Chief Commercial Officer) | Sale | 2,624 | 12.55 | 32,931 |
| 2021-01-05 | Muzikant Adam (Chief Business Officer) | Sale | 4,005 | 11.13 | 44,575 |
| 2021-01-05 | Willwerth Christina (Chief Strategy Officer) | Sale | 6,602 | 11.13 | 73,480 |
| 2021-01-05 | Levine Mark S. (General Counsel) | Sale | 6,829 | 11.13 | 76,006 |
| 2021-01-05 | Wentworth Kerry (Chief Regulatory Officer) | Sale | 6,829 | 11.13 | 76,006 |
| 2021-01-05 | Arkowitz David (Chief Financial Officer) | Sale | 6,073 | 11.13 | 67,592 |
| 2021-01-05 | Kelley Scott (Chief Medical Officer) | Sale | 6,829 | 11.13 | 76,006 |
| 2020-07-09 | Milinazzo Alan (Director) | Option Ex | 18,450 | 2.19 | 40,497 |
| 2020-05-26 | Clayman Michael D. (President and CEO) | Buy | 10,256 | 9.75 | 99,996 |
| 2020-05-26 | Stejbach Mark (Director) | Buy | 2,051 | 9.75 | 19,997 |
| 2020-05-07 | Arkowitz David (Chief Financial Officer) | Sale | 2,413 | 10.88 | 26,253 |
| 2020-01-03 | Willwerth Christina (Chief Strategy Officer) | Sale | 3,533 | .00 | 0 |
| 2020-01-03 | Levine Mark S. (General Counsel) | Sale | 3,724 | .00 | 0 |
| 2020-01-03 | Bodick Neil (Chief Scientific Officer) | Sale | 3,851 | .00 | 0 |
| 2020-01-03 | Wentworth Kerry (Chief Regulatory Officer) | Sale | 3,724 | .00 | 0 |
| 2020-01-03 | Arkowitz David (Chief Financial Officer) | Sale | 3,095 | .00 | 0 |
| 2020-01-03 | Kelley Scott (Chief Medical Officer) | Sale | 3,724 | .00 | 0 |
| 2019-10-06 | Bodick Neil (Chief Scientific Officer) | Option Ex | 4,568 | .00 | 0 |
| 2019-10-06 | Clayman Michael D. (President and CEO) | Option Ex | 14,800 | .00 | 0 |
| 2019-10-06 | Wentworth Kerry (Chief Regulatory Officer) | Option Ex | 3,400 | .00 | 0 |
| 2019-08-29 | Mahaffy Patrick J (Director) | Option Ex | 30,824 | .16 | 4,931 |
| 2019-08-08 | Clayman Michael D. (President and CEO) | Buy | 2,317 | 10.85 | 25,137 |
| 2019-08-08 | Colella Samuel D (Director) | Buy | 2,000 | 10.74 | 21,480 |
| 2019-05-31 | Arkowitz David (Chief Financial Officer) | Buy | 2,500 | 11.05 | 27,627 |
| 2019-05-23 | Merrifield C Ann (Director) | Buy | 8,000 | 12.64 | 101,120 |
| 2019-05-13 | Arkowitz David (Chief Financial Officer) | Buy | 4,000 | 11.99 | 47,960 |
| 2019-05-10 | Clayman Michael D. (President and CEO) | Buy | 4,012 | 12.48 | 50,065 |
| 2019-05-08 | Arkowitz David (Chief Financial Officer) | Sale | 2,248 | 10.06 | 22,614 |
| 2019-03-12 | Clayman Michael D. (President and CEO) | Buy | 4,046 | 12.36 | 50,008 |
| 2019-01-03 | Levine Mark S. (General Counsel) | Sale | 734 | 12.36 | 9,072 |
| 2019-01-03 | Bodick Neil (Chief Scientific Officer) | Sale | 746 | 12.36 | 9,220 |
| 2019-01-03 | Clayman Michael D. (President and CEO) | Sale | 3,278 | 12.36 | 40,516 |
| 2019-01-03 | Wentworth Kerry (Chief Regulatory Officer) | Sale | 622 | 12.36 | 7,687 |
| 2019-01-03 | Kelley Scott (Chief Medical Officer) | Sale | 622 | 12.36 | 7,687 |
| 2018-11-09 | Clayman Michael D. (President and CEO) | Buy | 5,000 | 17.09 | 85,475 |
| 2018-11-09 | Arkowitz David (Chief Financial Officer) | Buy | 4,000 | 16.55 | 66,220 |
| 2018-10-08 | Bodick Neil (Chief Scientific Officer) | Option Ex | 4,566 | .00 | 0 |
| 2018-10-08 | Clayman Michael D. (President and CEO) | Option Ex | 14,800 | .00 | 0 |
| 2018-08-09 | Clayman Michael D. (President and CEO) | Buy | 10,000 | 22.33 | 223,299 |
| 2018-08-09 | Arkowitz David (Chief Financial Officer) | Buy | 4,000 | 23.42 | 93,680 |
| 2018-07-03 | Bodick Neil (Chief Scientific Officer) | Sale | 16,492 | 25.00 | 412,300 |
| 2018-07-02 | Bodick Neil (Chief Scientific Officer) | Sale | 33,508 | 25.10 | 841,184 |
| 2018-05-11 | Bodick Neil (Chief Scientific Officer) | Option Ex | 37,702 | .16 | 6,145 |
| 2017-11-21 | Bodick Neil (Chief Scientific Officer) | Buy | 2,700 | 24.52 | 66,206 |
| 2017-11-08 | Clayman Michael D. (President and CEO) | Buy | 5,000 | 23.60 | 118,000 |
| 2017-10-06 | Bodick Neil (Chief Scientific Officer) | Option Ex | 4,566 | .00 | 0 |
| 2017-10-06 | Clayman Michael D. (President and CEO) | Option Ex | 14,800 | .00 | 0 |
| 2017-09-05 | Deniz Yamo (Chief Medical Officer) | Buy | 1,000 | 24.20 | 24,200 |
| 2017-09-01 | Deniz Yamo (Chief Medical Officer) | Buy | 3,000 | 24.25 | 72,750 |
| 2017-08-31 | Deniz Yamo (Chief Medical Officer) | Buy | 1,375 | 25.40 | 34,925 |
| 2017-06-16 | Stejbach Mark (Director) | Buy | 1,580 | 17.02 | 26,888 |
| 2017-06-05 | Clayman Michael D. (President and CEO) | Buy | 5,000 | 17.23 | 86,150 |
| 2017-06-05 | Colella Samuel D (Director) | Buy | 5,000 | 17.01 | 85,050 |
| 2017-05-15 | Bodick Neil (Chief Medical Officer) | Sale | 6,830 | 19.10 | 130,453 |
| 2017-04-17 | Bodick Neil (Chief Medical Officer) | Sale | 5,000 | 28.53 | 142,650 |
| 2017-03-23 | Driscoll Frederick W (Chief Financial Officer) | Sale | 3,000 | 23.00 | 69,000 |
| 2017-03-23 | Driscoll Frederick W (Chief Financial Officer) | Option Ex | 3,000 | 7.89 | 23,658 |
| 2017-03-17 | Bodick Neil (Chief Medical Officer) | Sale | 5,000 | 20.41 | 102,040 |
| 2017-02-28 | Driscoll Frederick W (Chief Financial Officer) | Sale | 33,434 | 20.19 | 674,999 |
| 2017-02-28 | Driscoll Frederick W (Chief Financial Officer) | Option Ex | 30,000 | 7.89 | 236,580 |
| 2017-02-24 | Bodick Neil (Chief Medical Officer) | Sale | 5,000 | 19.15 | 95,760 |
| 2017-01-20 | Bodick Neil (Chief Medical Officer) | Sale | 5,000 | 18.35 | 91,745 |
| 2016-12-21 | Bodick Neil (Chief Medical Officer) | Sale | 10,000 | 18.46 | 184,630 |
| 2016-11-23 | Clayman Michael D. (President and CEO) | Buy | 1,667 | 18.41 | 30,687 |
| 2016-11-22 | Clayman Michael D. (President and CEO) | Buy | 1,666 | 17.95 | 29,899 |
| 2016-11-21 | Clayman Michael D. (President and CEO) | Buy | 1,666 | 17.90 | 29,828 |
| 2016-11-21 | Colella Samuel D (Director) | Buy | 33,333 | 18.00 | 599,994 |
| 2016-06-21 | Colella Samuel D (Director) | Buy | 18,726 | 13.69 | 256,265 |
| 2016-06-20 | Colella Samuel D (Director) | Buy | 6,778 | 13.84 | 93,821 |
| 2016-06-14 | Merrifield C Ann (Director) | Buy | 1,000 | 13.39 | 13,387 |
| 2016-06-08 | Praeger Robin L. (10% Owner) | Buy | 714,285 | 14.00 | 9,999,990 |
| 2016-06-08 | Robertson Rebecca B (10% Owner) | Buy | 714,285 | 14.00 | 9,999,990 |
| 2016-06-08 | Colella Samuel D (Director) | Buy | 714,285 | 14.00 | 9,999,990 |
| 2016-05-23 | Clayman Michael D. (President and CEO) | Option Ex | 10,369 | .16 | 1,690 |
| 2016-05-20 | Clayman Michael D. (President and CEO) | Buy | 2,000 | 10.40 | 20,810 |
| 2016-05-19 | Bodick Neil (Chief Medical Officer) | Buy | 850 | 10.00 | 8,500 |
| 2016-05-19 | Clayman Michael D. (President and CEO) | Buy | 2,000 | 9.65 | 19,298 |
| 2016-05-18 | Bodick Neil (Chief Medical Officer) | Buy | 2,100 | 10.20 | 21,420 |
| 2016-05-18 | Clayman Michael D. (President and CEO) | Buy | 2,000 | 10.23 | 20,466 |
| 2016-05-17 | Bodick Neil (Chief Medical Officer) | Buy | 800 | 9.60 | 7,680 |
| 2016-05-17 | Clayman Michael D. (President and CEO) | Buy | 2,000 | 9.73 | 19,466 |
| 2016-05-17 | Driscoll Frederick W (Chief Financial Officer) | Buy | 2,500 | 9.87 | 24,667 |
| 2016-05-16 | Bodick Neil (Chief Medical Officer) | Buy | 1,250 | 9.40 | 11,750 |
| 2016-05-16 | Clayman Michael D. (President and CEO) | Buy | 2,000 | 9.51 | 19,026 |
| 2016-05-16 | Driscoll Frederick W (Chief Financial Officer) | Buy | 2,500 | 9.19 | 22,972 |
| 2015-09-11 | Merrifield C Ann (Director) | Buy | 1,000 | 23.00 | 23,000 |
| 2015-06-22 | Novo A/s (10% Owner) | Sale | 63,412 | 20.55 | 1,302,862 |
| 2015-06-19 | Novo A/s (10% Owner) | Sale | 50,888 | 20.07 | 1,021,220 |
| 2015-06-18 | Novo A/s (10% Owner) | Sale | 35,700 | 21.51 | 767,907 |
| 2015-03-24 | Clayman Michael D. (President and CEO) | Option Ex | 5,000 | .16 | 815 |
| 2015-03-16 | Bodick Neil (Chief Medical Officer) | Sale | 4,000 | 25.38 | 101,500 |
| 2015-03-10 | Bodick Neil (Chief Medical Officer) | Sale | 4,000 | 24.26 | 97,056 |
| 2015-03-04 | Bodick Neil (Chief Medical Officer) | Sale | 4,000 | 23.45 | 93,792 |
| 2015-02-26 | Bodick Neil (Chief Medical Officer) | Sale | 4,000 | 22.44 | 89,768 |
| 2014-12-17 | Novo A/s (10% Owner) | Buy | 500,000 | 17.00 | 8,500,000 |
| 2014-10-29 | Sofinnova Partners Sas | Sale | 10,000 | 20.00 | 200,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of FLXN listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Flexion Therapeutics Inc (symbol FLXN, CIK number 1419600) see the Securities and Exchange Commission (SEC) website.